Skip to content
value.today

electroCore, Inc.: peers

Change the peers

electroCore, Inc. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.

United Health Products, Inc.: the market cap on file is more than 60 days old or a last known value (no market-data feed for its exchange yet), so its valuation multiples and yields are shown but not ranked.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

electroCore, Inc., Microbot Medical Inc., United Health Products, Inc., Stereotaxis, Inc., Repro Med Systems, Harvard Bioscience, Inc., Nephros, Inc., Milestone Scientific Inc. side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasureelectroCore, Inc.base
ECOR · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Microbot Medical Inc.
MBOT · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
United Health Products, Inc.
UEEC · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Stereotaxis, Inc.
STXS · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Repro Med Systems
KRMD · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Harvard Bioscience, Inc.
HBIO · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Nephros, Inc.
NEPH · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Milestone Scientific Inc.
MLSS · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Group median
Size
Market cap (Better neither way: ranked highest first)$75 MOct 30, 2026 · Market data4th of 8$75 MOct 29, 2026 · Market data3rd of 8$72 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one5th of 8$92 MOct 30, 2026 · Market data2nd of 8$140 MOct 29, 2026 · Market data1st of 8$38 MOct 26, 2026 · Market data6th of 8$36 MOct 30, 2026 · Market data7th of 8$31 MOct 14, 2026 · Market data8th of 8$73 M8 ranked
Revenue (Better neither way: ranked highest first)$32 MFY2025 · SEC4th of 6————$32 MFY2025 · SEC3rd of 6$41 MFY2025 · SEC2nd of 6$87 MFY2025 · SEC1st of 6$19 MFY2025 · SEC5th of 6$9 MFY2025 · SEC6th of 6$32 M6 ranked
Net income (Higher is better)$-14 MFY2025 · SEC6th of 8$-13 MFY2025 · SEC5th of 8$-3 MFY2025 · SEC3rd of 8$-22 MFY2025 · SEC7th of 8$-3 MFY2025 · SEC2nd of 8$-57 MFY2025 · SEC8th of 8$1 MFY2025 · SEC1st of 8$-6 MFY2025 · SEC4th of 8$-9 M8 ranked
Employees (Better neither way: ranked highest first)83February 1, 2026 · Profile2nd of 543March 24, 2026 · Profile3rd of 5——131December 31, 2025 · Profile1st of 5————36December 31, 2025 · Profile4th of 515December 31, 2025 · Profile5th of 5435 ranked
Growth
Revenue growth (Higher is better)+27.2%FY2025 · SEC2nd of 675th85th————————+20.3%FY2025 · SEC4th of 670th79th+22.2%FY2025 · SEC3rd of 672nd81st-8.1%FY2025 · SEC6th of 615th13th+32.7%FY2025 · SEC1st of 678th87th+3.9%FY2025 · SEC5th of 634th42nd+21.3%6 ranked
Revenue growth, 3 years a year (Higher is better)+55.1%FY2025 · SEC1st of 690th96th————————+4.8%FY2025 · SEC4th of 641st52nd+13.8%FY2025 · SEC3rd of 662nd77th-8.6%FY2025 · SEC6th of 614th12th+23.5%FY2025 · SEC2nd of 676th88th+0.6%FY2025 · SEC5th of 629th35th+9.3%6 ranked
Earnings per share growth (Higher is better)————————————————————————+1000.0%FY2025 · SEConly one with it100th100th————+1000.0%—
Margins and returns
Gross margin (Higher is better)86.8%FY2025 · SEC1st of 688th95th————————52.7%FY2025 · SEC6th of 640th66th62.2%FY2025 · SEC3rd of 656th76th57.7%FY2025 · SEC5th of 649th72nd61.8%FY2025 · SEC4th of 655th76th71.5%FY2025 · SEC2nd of 670th84th62.0%6 ranked
Operating margin (Higher is better)-41.1%FY2025 · SEC3rd of 634th16th————————-68.3%FY2025 · SEC6th of 628th13th-7.2%FY2025 · SEC2nd of 650th30th-56.1%FY2025 · SEC4th of 630th14th6.1%FY2025 · SEC1st of 667th59th-63.5%FY2025 · SEC5th of 628th13th-48.6%6 ranked
Net margin (Higher is better)-43.6%FY2025 · SEC3rd of 632nd15th————————-66.8%FY2025 · SEC6th of 628th12th-6.4%FY2025 · SEC2nd of 652nd31st-65.5%FY2025 · SEC5th of 628th12th6.3%FY2025 · SEC1st of 672nd65th-63.8%FY2025 · SEC4th of 628th13th-53.7%6 ranked
Free cash flow margin (Higher is better)-25.8%FY2025 · SEC3rd of 535th15th————————-42.5%FY2025 · SEC5th of 529th13th-1.1%FY2025 · SEC2nd of 550th31st6.3%FY2025 · SEC1st of 565th59th————-32.8%FY2025 · SEC4th of 532nd14th-25.8%5 ranked
Return on equity (Higher is better)————-32.4%FY2025 · SEC3rd of 652nd23rd————-221.3%FY2025 · SEC6th of 69th4th-15.6%FY2025 · SEC2nd of 663rd30th-147.1%FY2025 · SEC5th of 616th7th12.7%FY2025 · SEC1st of 685th73rd-132.4%FY2025 · SEC4th of 618th8th-82.4%6 ranked
Valuation
P/E ratio (Better neither way: ranked highest first)————————————————————————18.7×price Oct 30, 2026 · Market dataonly one with it29th49th————18.7×—
Price to sales (Better neither way: ranked highest first)2.0×price Oct 30, 2026 · Market data4th of 633rd48th————————3.0×price Oct 30, 2026 · Market data2nd of 644th61st3.0×price Oct 29, 2026 · Market data3rd of 644th61st0.4×price Oct 26, 2026 · Market data6th of 67th13th1.6×price Oct 30, 2026 · Market data5th of 628th43rd3.3×price Oct 14, 2026 · Market data1st of 646th64th2.5×6 ranked
Price to book (Better neither way: ranked highest first)————1.0×price Oct 29, 2026 · Market data6th of 619th20th————6.8×price Oct 30, 2026 · Market data3rd of 675th83rd8.2×price Oct 29, 2026 · Market data2nd of 680th86th2.7×price Oct 26, 2026 · Market data5th of 646th59th3.5×price Oct 30, 2026 · Market data4th of 655th67th11.0×price Oct 14, 2026 · Market data1st of 685th90th5.1×6 ranked
Free cash flow yield (Higher is better)-11.0%price Oct 30, 2026 · Market data5th of 741st20th-17.4%price Oct 29, 2026 · Market data7th of 735th16th————-15.0%price Oct 30, 2026 · Market data6th of 737th17th-0.3%price Oct 29, 2026 · Market data2nd of 767th36th14.5%price Oct 26, 2026 · Market data1st of 797th93rd-1.6%price Oct 30, 2026 · Market data3rd of 763rd33rd-9.5%price Oct 14, 2026 · Market data4th of 743rd21st-9.5%7 ranked
Financial strength
Debt to equity (Lower is better)————————————————————2.6×FY2025 · SEConly one with it91st89th————————2.6×—
Interest cover (Higher is better)————————-20.6×FY2025 · SEC1st of 234th16th————————-37.4×FY2025 · SEC2nd of 225th11th————————-29.0×2 ranked
Piotroski F-score (Higher is better)——————————5 of 9FY2025 · SEConly one with it————5.0 of 9—
Scorecard
Scorecard (Higher is better)8 of 19FY2025 · Scorecard2nd of 82 of 12FY2025 · Scorecard6th of 81 of 8FY2025 · Scorecard7th of 82 of 22FY2025 · Scorecard8th of 88 of 20FY2025 · Scorecard3rd of 86 of 23FY2025 · Scorecard4th of 812 of 21FY2025 · Scorecard1st of 84 of 20FY2025 · Scorecard5th of 823% passed8 ranked
Valuation checks (Higher is better)1 of 5FY2025 · Scorecard4th of 71 of 4FY2025 · Scorecard3rd of 7——0 of 5FY2025 · Scorecard5th of 70 of 5FY2025 · Scorecard5th of 73 of 6FY2025 · Scorecard2nd of 74 of 6FY2025 · Scorecard1st of 70 of 5FY2025 · Scorecard5th of 720% passed7 ranked
Growth checks (Higher is better)5 of 6FY2025 · Scorecard1st of 80 of 2FY2025 · Scorecard7th of 81 of 2FY2025 · Scorecard4th of 81 of 6FY2025 · Scorecard6th of 84 of 6FY2025 · Scorecard3rd of 80 of 6FY2025 · Scorecard7th of 85 of 6FY2025 · Scorecard1st of 82 of 6FY2025 · Scorecard5th of 842% passed8 ranked
Profitability checks (Higher is better)1 of 4FY2025 · Scorecard2nd of 80 of 3FY2025 · Scorecard5th of 80 of 2FY2025 · Scorecard5th of 80 of 5FY2025 · Scorecard5th of 81 of 5FY2025 · Scorecard3rd of 80 of 5FY2025 · Scorecard5th of 82 of 5FY2025 · Scorecard1st of 81 of 5FY2025 · Scorecard3rd of 810% passed8 ranked
Financial health checks (Higher is better)1 of 3FY2025 · Scorecard4th of 81 of 2FY2025 · Scorecard2nd of 80 of 3FY2025 · Scorecard8th of 81 of 3FY2025 · Scorecard4th of 82 of 3FY2025 · Scorecard1st of 82 of 5FY2025 · Scorecard3rd of 81 of 3FY2025 · Scorecard4th of 81 of 3FY2025 · Scorecard4th of 833% passed8 ranked
Shareholder returns checks (Higher is better)0 of 1FY2025 · Scorecard3rd of 80 of 1FY2025 · Scorecard3rd of 80 of 1FY2025 · Scorecard3rd of 80 of 3FY2025 · Scorecard3rd of 81 of 1FY2025 · Scorecard1st of 81 of 1FY2025 · Scorecard1st of 80 of 1FY2025 · Scorecard3rd of 80 of 1FY2025 · Scorecard3rd of 80% passed8 ranked
Ownership
Held by institutions (Better neither way: ranked highest first)15.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 817.4%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 80.1%2026-Q2 · 13F8th of 841.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 846.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 830.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 823.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 85.6%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 820.6%8 ranked
Institutions holding (Better neither way: ranked highest first)402026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 8742026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 812026-Q2 · 13F8th of 81022026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 8852026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 8302026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 8362026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 8322026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 8388 ranked
Institutional holding, change over the quarter (Better neither way: ranked highest first)+1.4 pp2026-Q2 against 2026-Q1 · 13F2nd of 8-4.3 pp2026-Q2 against 2026-Q1 · 13F8th of 80.0 pp2026-Q2 against 2026-Q1 · 13F3rd of 8-0.9 pp2026-Q2 against 2026-Q1 · 13F6th of 8-0.3 pp2026-Q2 against 2026-Q1 · 13F4th of 8+26.7 pp2026-Q2 against 2026-Q1 · 13F1st of 8-1.5 pp2026-Q2 against 2026-Q1 · 13F7th of 8-0.3 pp2026-Q2 against 2026-Q1 · 13F5th of 8-0.3 pp8 ranked
Dividends
Dividend yield (Higher is better)————————————0.0%FY2025 · SEConly one with it6th2nd————————————————0.0%—
Shareholder yield (Higher is better)————————————0.0%FY2025 · SEConly one with it7th3rd————————————————0.0%—

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = electroCore, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Microbot Medical Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; United Health Products, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Stereotaxis, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Repro Med Systems: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Harvard Bioscience, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Nephros, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Milestone Scientific Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.

Where each stands in its sector and country: Operating margin#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Operating margin: each company's figure and its percentile in its sector and its country
CompanyOperating marginIn its sectorIn its country
electroCore, Inc.-41.1%FY2025
34th percentile in Healthcaremedian -7.7%, 674 companies
16th percentile in USAmedian 3.5%, 2,594 companies
Microbot Medical Inc.———
United Health Products, Inc.———
Stereotaxis, Inc.-68.3%FY2025
28th percentile in Healthcaremedian -7.7%, 674 companies
13th percentile in USAmedian 3.5%, 2,594 companies
Repro Med Systems-7.2%FY2025
50th percentile in Healthcaremedian -7.7%, 674 companies
30th percentile in USAmedian 3.5%, 2,594 companies
Harvard Bioscience, Inc.-56.1%FY2025
30th percentile in Healthcaremedian -7.7%, 674 companies
14th percentile in USAmedian 3.5%, 2,594 companies
Nephros, Inc.6.1%FY2025
67th percentile in Healthcaremedian -7.7%, 674 companies
59th percentile in USAmedian 3.5%, 2,594 companies
Milestone Scientific Inc.-63.5%FY2025
28th percentile in Healthcaremedian -7.7%, 674 companies
13th percentile in USAmedian 3.5%, 2,594 companies

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$30 M$60 M$91 M$121 M20102012201420162018202020222024electroCore, Inc. $32 MMicrobot Medical Inc. $0 MUnited Health Products, Inc. $0 MStereotaxis, Inc. $32 MRepro Med Systems $41 MHarvard Bioscience, Inc. $87 MNephros, Inc. $19 MMilestone Scientific Inc. $9 M

Rank in the group

1st2nd3rd4th5th6th7th201120122013201420152016201720182019202020212022202320242025electroCore, Inc.: 5th of 6 in 2017electroCore, Inc.: 6th of 7 in 2018electroCore, Inc.: 6th of 7 in 2019electroCore, Inc.: 6th of 7 in 2020electroCore, Inc.: 6th of 7 in 2021electroCore, Inc.: 6th of 7 in 2022electroCore, Inc.: 4th of 6 in 2023electroCore, Inc.: 4th of 6 in 2024electroCore, Inc.: 4th of 6 in 2025electroCore, Inc.Microbot Medical Inc.: 6th of 6 in 2011Microbot Medical Inc.: 6th of 6 in 2012Microbot Medical Inc.: 6th of 6 in 2013Microbot Medical Inc.: 6th of 6 in 2015Microbot Medical Inc.United Health Products, Inc.: 6th of 6 in 2014United Health Products, Inc.: 6th of 6 in 2016United Health Products, Inc.: 6th of 6 in 2017United Health Products, Inc.: 7th of 7 in 2018United Health Products, Inc.: 7th of 7 in 2019United Health Products, Inc.: 7th of 7 in 2020United Health Products, Inc.: 7th of 7 in 2021United Health Products, Inc.: 7th of 7 in 2022United Health Products, InStereotaxis, Inc.: 2nd of 6 in 2011Stereotaxis, Inc.: 2nd of 6 in 2012Stereotaxis, Inc.: 2nd of 6 in 2013Stereotaxis, Inc.: 2nd of 6 in 2014Stereotaxis, Inc.: 2nd of 6 in 2015Stereotaxis, Inc.: 2nd of 6 in 2016Stereotaxis, Inc.: 2nd of 6 in 2017Stereotaxis, Inc.: 2nd of 7 in 2018Stereotaxis, Inc.: 2nd of 7 in 2019Stereotaxis, Inc.: 2nd of 7 in 2020Stereotaxis, Inc.: 2nd of 7 in 2021Stereotaxis, Inc.: 2nd of 7 in 2022Stereotaxis, Inc.: 3rd of 6 in 2023Stereotaxis, Inc.: 3rd of 6 in 2024Stereotaxis, Inc.: 3rd of 6 in 2025Stereotaxis, Inc.Repro Med Systems: 4th of 6 in 2011Repro Med Systems: 4th of 6 in 2012Repro Med Systems: 4th of 6 in 2013Repro Med Systems: 3rd of 6 in 2014Repro Med Systems: 3rd of 6 in 2015Repro Med Systems: 3rd of 6 in 2016Repro Med Systems: 3rd of 7 in 2018Repro Med Systems: 3rd of 7 in 2019Repro Med Systems: 3rd of 7 in 2020Repro Med Systems: 3rd of 7 in 2021Repro Med Systems: 3rd of 7 in 2022Repro Med Systems: 2nd of 6 in 2023Repro Med Systems: 2nd of 6 in 2024Repro Med Systems: 2nd of 6 in 2025Repro Med SystemsHarvard Bioscience, Inc.: 1st of 6 in 2011Harvard Bioscience, Inc.: 1st of 6 in 2012Harvard Bioscience, Inc.: 1st of 6 in 2013Harvard Bioscience, Inc.: 1st of 6 in 2014Harvard Bioscience, Inc.: 1st of 6 in 2015Harvard Bioscience, Inc.: 1st of 6 in 2016Harvard Bioscience, Inc.: 1st of 6 in 2017Harvard Bioscience, Inc.: 1st of 7 in 2018Harvard Bioscience, Inc.: 1st of 7 in 2019Harvard Bioscience, Inc.: 1st of 7 in 2020Harvard Bioscience, Inc.: 1st of 7 in 2021Harvard Bioscience, Inc.: 1st of 7 in 2022Harvard Bioscience, Inc.: 1st of 6 in 2023Harvard Bioscience, Inc.: 1st of 6 in 2024Harvard Bioscience, Inc.: 1st of 6 in 2025Harvard Bioscience, Inc.Nephros, Inc.: 5th of 6 in 2011Nephros, Inc.: 5th of 6 in 2012Nephros, Inc.: 5th of 6 in 2013Nephros, Inc.: 5th of 6 in 2014Nephros, Inc.: 5th of 6 in 2015Nephros, Inc.: 5th of 6 in 2016Nephros, Inc.: 4th of 6 in 2017Nephros, Inc.: 5th of 7 in 2018Nephros, Inc.: 4th of 7 in 2019Nephros, Inc.: 4th of 7 in 2020Nephros, Inc.: 5th of 7 in 2021Nephros, Inc.: 4th of 7 in 2022Nephros, Inc.: 5th of 6 in 2023Nephros, Inc.: 5th of 6 in 2024Nephros, Inc.: 5th of 6 in 2025Nephros, Inc.Milestone Scientific Inc.: 3rd of 6 in 2011Milestone Scientific Inc.: 3rd of 6 in 2012Milestone Scientific Inc.: 3rd of 6 in 2013Milestone Scientific Inc.: 4th of 6 in 2014Milestone Scientific Inc.: 4th of 6 in 2015Milestone Scientific Inc.: 4th of 6 in 2016Milestone Scientific Inc.: 3rd of 6 in 2017Milestone Scientific Inc.: 4th of 7 in 2018Milestone Scientific Inc.: 5th of 7 in 2019Milestone Scientific Inc.: 5th of 7 in 2020Milestone Scientific Inc.: 4th of 7 in 2021Milestone Scientific Inc.: 5th of 7 in 2022Milestone Scientific Inc.: 6th of 6 in 2023Milestone Scientific Inc.: 6th of 6 in 2024Milestone Scientific Inc.: 6th of 6 in 2025Milestone Scientific Inc.
Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearelectroCore, Inc.Microbot Medical Inc.United Health Products, Inc.Stereotaxis, Inc.Repro Med SystemsHarvard Bioscience, Inc.Nephros, Inc.Milestone Scientific Inc.
2025$32 MSEC4th——$32 MSEC3rd$41 MSEC2nd$87 MSEC1st$19 MSEC5th$9 MSEC6th
2024$25 MSEC4th——$27 MSEC3rd$34 MSEC2nd$94 MSEC1st$14 MSEC5th$9 MSEC6th
2023$16 MSEC4th——$27 MSEC3rd$29 MSEC2nd$112 MSEC1st$14 MSEC5th$10 MSEC6th
2022$9 MSEC6th—$0 MSEC7th$28 MSEC2nd$28 MSEC3rd$113 MSEC1st$10 MSEC4th$9 MSEC5th
2021$5 MSEC6th—$0 MSEC7th$35 MSEC2nd$23 MSEC3rd$119 MSEC1st$10 MSEC5th$10 MSEC4th
2020$4 MSEC6th—$0 MSEC7th$27 MSEC2nd$24 MSEC3rd$102 MSEC1st$9 MSEC4th$5 MSEC5th
2019$2 MSEC6th—$0 MSEC7th$29 MSEC2nd$23 MSEC3rd$116 MSEC1st$10 MSEC4th$8 MSEC5th
2018$1 MSEC6th—$0 MSEC7th$29 MSEC2nd$17 MSEC3rd$121 MSEC1st$6 MSEC5th$10 MSEC4th
2017$1 MSEC5th—$0 MSEC6th$31 MSEC2nd—$77 MSEC1st$4 MSEC4th$11 MSEC3rd
2016——$0 MSEC6th$32 MSEC2nd$12 MSEC3rd$105 MSEC1st$2 MSEC5th$10 MSEC4th
2015—$0 MSEC6th—$38 MSEC2nd$12 MSEC3rd$109 MSEC1st$2 MSEC5th$9 MSEC4th
2014——$0 MSEC6th$35 MSEC2nd$11 MSEC3rd$109 MSEC1st$2 MSEC5th$10 MSEC4th

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.

Suggested peers of electroCore, Inc.#

Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • Microbot Medical Inc.MBOT · 🇺🇸 USA
    Same industry: Medical Instruments · Similar size: $75 M market cap against $75 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $75 M (Oct 29, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • United Health Products, Inc.UEEC · 🇺🇸 USA
    Same industry: Medical Instruments · Similar size: $72 M market cap against $75 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $72 M (last known, Jul 30, 2023)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Stereotaxis, Inc.STXS · 🇺🇸 USA
    Same industry: Medical Instruments · Similar size: $92 M market cap against $75 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $92 M (Oct 30, 2026) · revenue $32 M (year to December 2025)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    In the group
  • Repro Med SystemsKRMD · 🇺🇸 USA
    Same industry: Medical Instruments · Similar size: $140 M market cap against $75 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $140 M (Oct 29, 2026) · revenue $41 M (year to December 2025)
    96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)
    In the group
  • Harvard Bioscience, Inc.HBIO · 🇺🇸 USA
    Same industry: Medical Instruments · Similar size: $38 M market cap against $75 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $38 M (Oct 26, 2026) · revenue $87 M (year to December 2025)
    96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)
    In the group
  • Nephros, Inc.NEPH · 🇺🇸 USA
    Same industry: Medical Instruments · Similar size: $36 M market cap against $75 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $36 M (Oct 30, 2026) · revenue $19 M (year to December 2025)
    95 of 100 (industry or sector 50 + size 25 + country 15 + figures on file 5)
    In the group
  • Milestone Scientific Inc.MLSS · 🇺🇸 USA
    Same industry: Medical Instruments · Similar size: $31 M market cap against $75 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $31 M (Oct 14, 2026) · revenue $9 M (year to December 2025)
    94 of 100 (industry or sector 50 + size 24 + country 15 + figures on file 5)
    In the group
  • Utah Medical Products, Inc.UTMD · 🇺🇸 USA
    Same industry: Medical Instruments · Similar size: $190 M market cap against $75 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $190 M (Oct 30, 2026) · revenue $39 M (year to December 2025)
    94 of 100 (industry or sector 50 + size 24 + country 15 + figures on file 5)
    + Add
  • Daxor CorporationDXR · 🇺🇸 USA
    Same industry: Medical Instruments · Similar size: $61 M market cap against $75 M · Same country: USA
    Market cap $61 M (Aug 1, 2026) · revenue $1 M (year to December 2011)
    94 of 100 (industry or sector 50 + size 29 + country 15)
    + Add
  • Pro-Dex, Inc.PDEX · 🇺🇸 USA
    Same industry: Medical Instruments · Similar size: $199 M market cap against $75 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $199 M (Oct 28, 2026) · revenue $78 M (year to June 2026)
    94 of 100 (industry or sector 50 + size 24 + country 15 + figures on file 5)
    + Add
  • InfuSystems HoldingsINFU · 🇺🇸 USA
    Same industry: Medical Instruments · Similar size: $255 M market cap against $75 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $255 M (Sep 28, 2026) · revenue $143 M (year to December 2025)
    92 of 100 (industry or sector 50 + size 22 + country 15 + figures on file 5)
    + Add
  • OraSure Technologies, Inc.OSUR · 🇺🇸 USA
    Same industry: Medical Instruments · Similar size: $262 M market cap against $75 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $262 M (Oct 23, 2026) · revenue $115 M (year to December 2025)
    92 of 100 (industry or sector 50 + size 22 + country 15 + figures on file 5)
    + Add

Any figure over the years, other peers or a saved group: open this group in the peer workspace.